Compare INSM & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | WST |
|---|---|---|
| Founded | 1988 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | 25.6B |
| IPO Year | 2000 | 2004 |
| Metric | INSM | WST |
|---|---|---|
| Price | $118.52 | $337.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 7 |
| Target Price | $201.17 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 2.9M | 381.2K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 4.07 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $182.31 | $6.76 |
| Revenue Next Year | $65.19 | $6.22 |
| P/E Ratio | ★ N/A | $85.04 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $90.39 | $223.83 |
| 52 Week High | $212.75 | $386.00 |
| Indicator | INSM | WST |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 43.79 |
| Support Level | $97.66 | $323.60 |
| Resistance Level | $119.54 | $359.48 |
| Average True Range (ATR) | 4.08 | 6.82 |
| MACD | -1.32 | -0.79 |
| Stochastic Oscillator | 2.22 | 16.13 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.